IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 04, 2024 09:00 ET
|
IO Biotech
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
September 14, 2024 02:30 ET
|
IO Biotech
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals...
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
August 30, 2024 16:05 ET
|
IO Biotech
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...
IO Biotech Announces Participation in Upcoming Investor Conferences
August 26, 2024 16:05 ET
|
IO Biotech
IO Biotech Announces Participation in Upcoming Investor Conferences
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 13, 2024 07:05 ET
|
IO Biotech
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024
July 25, 2024 16:05 ET
|
IO Biotech
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech to Present at Jefferies Global Healthcare Conference
May 23, 2024 08:30 ET
|
IO Biotech
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 14, 2024 07:55 ET
|
IO Biotech
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine,...
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:30 ET
|
IO Biotech
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
April 15, 2024 08:30 ET
|
IO Biotech
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness